Press release Stockholm October 3, 2014
Clarification regarding the postponed launch of "Brighter One".
The postponement of the release of "Brighter One" as the press announced
2014-09-19 is due to that some parts of lancet mechanism and its casing produced
with production tools exhibited inferior user experience and quality compared to
the prototypes. This prompted an analysis that resulted in the revision of the
design as announced and with subsequent new orders and manufacturing of
production tools.
Brighter has developed a unique and patented integrated method for simplifying
self-care of diabetes resulting in a device that combines diagnostics,
medication and journaling - facilitating a normal way of life for millions of
diabetics worldwide.
- It's rare that series production parts result in inferior user experience and
quality. We had the option of revising the design of the lancet mechanism and
its casing and a continuous (expensive) manual trimming on each unit during
serial production. Revision of design leads to new tools to be ordered,
manufactured and fine-tuned, which takes time and is the reason for the delay.
We weighed the pros and cons of the two options and decided that the revision of
the design, and thus the delay, was the better alternative. The result of the
decision is both a better product and a more cost-efficient production. All
other parts of the device are in line and will not be affected by the revision
of the lancet mechanism and its lid, says Brighter's CEO Truls Sjöstedt.
The CE-certification process, which is conducted in parallel with the
manufacturing set-up, will, just as before, follow the timeline for the product.
As the CE-certificate is ultimately granted the finished product, the revision
of the design of the lancet mechanism and its casing results in that the grant
will be awarded with the postponed launch.
About Brighter AB (publ)
Brighter has developed a unique and patented integrated method for simplifying
self-care of diabetes resulting in a device that combines diagnostics,
medication and journaling - facilitating a normal way of life for millions of
diabetics worldwide.
The Company's shares are listed on NASDAQOMX First North/BRIG.
Visit our website and subscribe to press releases: www.brightercompany.com
Follow us on:
Facebook
LinkedIn
Twitter: @Brighter_AB
Certified Advisor
Brighter's Certified Advisor on Nasdaq OMX First North is Pareto Securities AB.
For further information, please contact:
Henrik Norström, COO Truls Sjöstedt, VD
Telephone: +46 733 40 30 45 Telephone : +46 709 73 46 00
Email: Email:
henrik.norstrom@brightercompany.com truls.sjostedt@brightercompany.com
[HUG#1860461]
